The new PathoKey MP UTI ID and AMR PCR test is compatible with common real-time PCR cyclers, such as the Rotor-Gene Q 5/6 plex platforms and QuantStudio 5 real-time PCR system
Vela Diagnostics launches new multiplex PathoKey MP UTI ID and AMR PCR Test. (Credit: Gerd Altmann from Pixabay)
Molecular solutions provider Vela Diagnostics has launched a new multiplex PathoKey MP UTI ID and AMR PCR Test for research use only.
The test is intended for the in vitro detection and identification of 14 pathogens that cause urinary tract infections (UTI), as well as 14 antimicrobial resistance (AMR) genes encoding resistance to five antibiotics.
Vela Diagnostics’s latest product is compatible with real-time PCR cyclers like Rotor-Gene Q 5/6 plex platforms and QuantStudio 5 real-time PCR system.
When utilised with the Sentosa SA201 or Applied Biosystems 7500 Fast Dx, Vela Diagnostics’ patented Sentosa SA201 Reporter can generate a report that consolidates pathogen and AMR results for each sample.
The firm said that high-throughput laboratories can choose from its highly automated solutions, which include the Sentosa SX101 instrument for extraction and PCR preparation.
With an option for both manual and automatic workflow, it can generate results in four hours in less than 30 minutes.
For even better throughput, the second automated workflow comprises the KingFisher Flex instrument, said Vela Diagnostics.
The company also mentioned that laboratories with lower throughput can use the manual workflow option to prevent wastage as batching is not required.
Vela Diagnostics research and development head Dr Charlie Lee said: “When designing our PathoKey MP UTI ID and AMR PCR Test, we prioritized automation, flexibility and comprehensive report generation.
“We believe that through comprehensive data analysis and reporting, VELA’s UTI solution will give timely and insightful results to customers.
“Being a 2-in-1 test, it is able to detect and differentiate between the UTI-inducing pathogens as well as their AMR profiles in one run, improving lab efficiency.”
Vela Diagnostics chairman and CEO Sam Dajani said: “Laboratories wishing to gain further insights into their samples will have the reflex option of using our PathoKey SQ FLEX Pathogen ID Assay, which will be launched in the third quarter of 2022.
“The NGS-based assay enables users to delve into the microbial makeup of their samples, including the identification of pathogens which may be missed by PCR-based tests.”